Yes, that was what I was wondering myself, at what point would leronlimab be placed on the NCCN list. It seems once some drugs get approved for one cancer and get put on the NCCN list for another cancer, the don’t bother seeking fda approval for the second cancer. Apparently NCCN is the big one, but there are a few others. Also if leronlimab is approved for mTNBC, at what point does NCCN list it as a ccr5 biomarker?(which is why I wanted to look at boimarkers on their site). I assume it will be some time before FDA approval for moa, but I’m sure others here know a lot about this and will give their opinion.